andresr/E+ via Getty Images Thesis I thought West Pharmaceutical Services, Inc. ( WST ) delivered a pretty clear beat-and-raise quarter . We have a 1Q26 adjusted EPS of $2.13 coming in about $0.45 ahead of expectations, and revenue reaching $844.9 million, a figure that also beats expectations by over $65 million. So there is clearly some strong underlying demand here. Their growth was also pretty...
andresr/E+ via Getty Images Thesis I thought West Pharmaceutical Services, Inc. ( WST ) delivered a pretty clear beat-and-raise quarter . We have a 1Q26 adjusted EPS of $2.13 coming in about $0.45 ahead of expectations, and revenue reaching $844.9 million, a figure that also beats expectations by over $65 million. So there is clearly some strong underlying demand here. Their growth was also pretty robust across the board, with revenue up about 21% since last year and EPS rising over 50%. Their free cash flow also remained quite solid at $47.2 million, even though there was some continued investment and heavy share buybacks at about $298 million in 1Q26 alone. Overall, I would be Buy-rated on West here since I see a rather compelling combination of durable growth drivers, margin expansion, and execution, as I’ll explain. My upside case would be that we see continued strength in High-Value Product components, biologics demand, and also the Annex 1-driven mix shift that should allow the company to outperform its own conservative guidance. This scenario would potentially drive EPS above the high end of $8.75 and support further multiple expansion going forward. West Pharmaceutical Services, Inc. 1Q26 overview West closed about 13% higher yesterday. I thought they delivered pretty strong 1Q26 earnings , with some aspects of their performance well ahead of the typical large-cap healthcare suppliers. If we start with net sales, they rose about 21% year-over-year to reach $844.9 million, with organic growth in the range of 15.3%. So it’s safe to say that a lot of the expansion here came from underlying demand rather than currency or acquisitions. Profitability also improved, and even faster than revenue. Operating profit margin expanded from 15.3% to 21.0%, while their diluted EPS also jumped about 56% to $1.92, or $2.13 on an adjusted basis. I think we can put this margin expansion down to both operating leverage and some favorable product mix shifts toward higher-margin o...
Scinai Immunotherapeutics ( SCNI ) has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and accredited investors, for the purchase and sale of 5.21M American Depositary Shares (ADSs), each representing 4,000 ordinary shares, at a purchase price of $0.48 per ADS. It will also purchase Series A warrants to purch...
Scinai Immunotherapeutics ( SCNI ) has entered into a securities purchase agreement with an institutional life sciences investor, as well as with new and existing institutional and accredited investors, for the purchase and sale of 5.21M American Depositary Shares (ADSs), each representing 4,000 ordinary shares, at a purchase price of $0.48 per ADS. It will also purchase Series A warrants to purchase up to 5.21M ADSs at an exercise price of $0.48 each, exercisable immediately with a term of two years, and a Series B warrant to purchase up to 5.21M ADSs at an exercise price of $0.55 per ADS, exercisable immediately with a term of five years. In addition, the Company entered into a warrant inducement agreement with an existing institutional investor of the company for the immediate exercise of warrants to purchase up to 229,310 ADSs of its ordinary shares at an exercise price of $0.48 per ADS. In consideration for the immediate exercise in full of the existing warrants for cash, the investor will receive in a private placement new unregistered warrants to purchase up to 458,621 ADSs. The new warrants will have an exercise price of $0.55 per ADS, will be exercisable immediately, and will expire five years from the date of issuance. The aggregate gross proceeds from the private placement and the warrant inducement transaction are approximately $2.61 million, and the closing of the transactions is expected to occur on or about April 27, 2026. Scinai intends to use the net proceeds, together with existing cash resources, to support the expansion of its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. SCNI +96.05% premarket to $0.894. Source: Press Release More on Scinai Immunotherapeutics Scinai Immunotherapeutics receives Nasdaq notice over minimum bid price requirement Financial information for Scinai Immunotherapeutics
Shares in plumbing and paints company Masco (NYSE: MAS) rose by 13.2% in the week to Friday morning. The move comes after a surprisingly strong set of first-quarter 2026 earnings was released earlier in the week. A combination of soaring raw material prices and the absence of a significant recovery in the housing market and weak consumer market is creating what Masco's management describes as "a d...
Shares in plumbing and paints company Masco (NYSE: MAS) rose by 13.2% in the week to Friday morning. The move comes after a surprisingly strong set of first-quarter 2026 earnings was released earlier in the week. A combination of soaring raw material prices and the absence of a significant recovery in the housing market and weak consumer market is creating what Masco's management describes as "a dynamic macroeconomic and geopolitical environment." Still, you wouldn't know it from looking at the company's first quarter 2026 results. Company sales rose 4% in local currency to $1.92 billion in the quarter, with an impressive increase in operating profit margin to 16.9% from 16% in the same quarter of 2025. Given that the adjusted gross profit margin was flat at 36%, the increase in operating profit clearly came from keeping sales, general, and administrative (SG&A) costs under control at $366 million, compared to $358 million in last year's first quarter. Continue reading
JHVEPhoto Samsung's ( SSNLF ) production of its foundry and memory chips at its South Korean fabs plunged 58% and 18%, respectively, the company's union said, according to Reuters. The drop occurred during the overnight shift, as the union has demanded higher pay for its workers, more in line with what workers at competitor SK hynix (HXSC.F) are paid. Many workers who were set to work the shift th...
JHVEPhoto Samsung's ( SSNLF ) production of its foundry and memory chips at its South Korean fabs plunged 58% and 18%, respectively, the company's union said, according to Reuters. The drop occurred during the overnight shift, as the union has demanded higher pay for its workers, more in line with what workers at competitor SK hynix (HXSC.F) are paid. Many workers who were set to work the shift that spanned from 10 p.m. Thursday to 6 a.m. Friday simply skipped work, the news outlet added , citing the union. Samsung's factories operate 24 hours a day and have three shifts. The South Korean tech giant did not immediately respond to a request for comment from Seeking Alpha. Thousands of Samsung Electronics workers rallied at a factory complex south of Seoul earlier this week . Union organizers and police put the number of protesters at 40,000, making the demonstration the largest to date for Samsung. If the workers demands are not met, they plan to strike for 18 days from May 21. More on Samsung Electronics Samsung: Q1 Profit Guide Well Ahead Of Consensus, Remains A Buy Samsung Brings AI And Hardware Refinements To S26 Samsung Electronics Co., Ltd. (SSNLF) Q4 2025 Earnings Call Transcript Samsung workers threaten long strike, protest over pay gap with SK hynix Samsung SDI lands Mercedes-Benz EV battery supply deal - report
First Hawaiian ( FHB ) declares $0.26/share quarterly dividend , in line with previous. Forward yield 3.86% Payable May 29; for shareholders of record May 18; ex-div May 18. See FHB Dividend Scorecard, Yield Chart, & Dividend Growth. More on First Hawaiian First Hawaiian, Inc. (FHB) Shareholder/Analyst Call Prepared Remarks Transcript Slow Growth Keeps Me On The Sidelines For First Hawaiian First ...
First Hawaiian ( FHB ) declares $0.26/share quarterly dividend , in line with previous. Forward yield 3.86% Payable May 29; for shareholders of record May 18; ex-div May 18. See FHB Dividend Scorecard, Yield Chart, & Dividend Growth. More on First Hawaiian First Hawaiian, Inc. (FHB) Shareholder/Analyst Call Prepared Remarks Transcript Slow Growth Keeps Me On The Sidelines For First Hawaiian First Hawaiian, Inc. 2025 Q4 - Results - Earnings Call Presentation First Hawaiian outlines 3%-4% loan growth and $520M expense target for 2026 amid strong deposit trends First Hawaiian GAAP EPS of $0.56 beats by $0.01, revenue of $225.85M beats by $0.42M
primeimages/iStock via Getty Images Inflation Pressures Build, But Starting Point Matters Back-and-forth developments over the weekend around the Strait of Hormuz have added near-term volatility to energy markets. That uncertainty is feeding into oil prices and reinforcing questions about how persistent energy-driven inflation pressures could become, particularly if disruption risks continue to eb...
primeimages/iStock via Getty Images Inflation Pressures Build, But Starting Point Matters Back-and-forth developments over the weekend around the Strait of Hormuz have added near-term volatility to energy markets. That uncertainty is feeding into oil prices and reinforcing questions about how persistent energy-driven inflation pressures could become, particularly if disruption risks continue to ebb and flow. Although the March U.S. core inflation data was a touch softer than consensus expectations, near-term core inflation could continue to rise amid the geopolitical tensions. While energy prices do not directly enter core inflation, second-round effects are already expected to emerge through channels such as transportation and services. For instance, many airlines have already begun raising airfare and checked baggage fees to offset higher jet fuel costs. This indirect transmission reinforces that even targeted shocks can have wider inflation implications across the economy. But we think investors can still take some comfort in knowing that this inflation cycle might be different than the 2022 experience. Why This Cycle Differs From 2022 The current inflation backdrop differs from the conditions that drove the 2022 surge. At that time, inflation was fueled by both supply disruptions and a strong demand rebound, alongside an overheated labor market and elevated shelter costs. These forces pushed core inflation to significantly higher levels than today. U.S. core inflation peaked at nearly 7% year-over-year in 2022, compared to a core inflation rate of 2.6% year-over-year in March 2026. By contrast, the current inflation backdrop starts from a more balanced position. The U.S. labor market, while stabilizing, is not overheated. And in some parts of the world (e.g., Canada and the United Kingdom), the labor market might even be weaker than longer-term equilibrium levels. Meanwhile, interest rates are no longer near zero and instead sit at neutral or restrictive levels....
(RTTNews) - President Donald Trump asked not to "rush" to resolve the Iran war, as tensions persisted over the control of the Strait of Hormuz. Reports said that Irani deligation will be reaching Pakistani for a second round of talks.
(RTTNews) - President Donald Trump asked not to "rush" to resolve the Iran war, as tensions persisted over the control of the Strait of Hormuz. Reports said that Irani deligation will be reaching Pakistani for a second round of talks.